Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patterns of long-term thienopyridine therapy and outcomes in patients with acute coronary syndrome treated with coronary stenting: Observations from the TIMI-38 Coronary Stent Registry.
Bonaca MP, Murphy SA, Miller D, Herrman JP, Gottlieb S, Keltai M, Menozzi A, Nicolau JC, Widimsky P, Antman EM, Wiviott SD. Bonaca MP, et al. Clin Cardiol. 2014 May;37(5):293-9. doi: 10.1002/clc.22247. Epub 2014 Feb 14. Clin Cardiol. 2014. PMID: 24532082 Free PMC article. Clinical Trial.
Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial).
Bonaca MP, Wiviott SD, Sabatine MS, Buros J, Murphy SA, Scirica BM, Rifai N, Antman EM, Morrow DA. Bonaca MP, et al. Am J Cardiol. 2007 Feb 1;99(3):344-8. doi: 10.1016/j.amjcard.2006.08.035. Epub 2006 Nov 30. Am J Cardiol. 2007. PMID: 17261395 Clinical Trial.
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Bonaca MP, Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E. Morrow DA, et al. Among authors: bonaca mp. Circulation. 2009 Jun 2;119(21):2758-64. doi: 10.1161/CIRCULATIONAHA.108.833665. Epub 2009 May 18. Circulation. 2009. PMID: 19451347 Clinical Trial.
Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.
Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E; TRA 2(o)P-TIMI 50 Investigators. Morrow DA, et al. Among authors: bonaca mp. Am Heart J. 2009 Sep;158(3):335-341.e3. doi: 10.1016/j.ahj.2009.06.027. Am Heart J. 2009. PMID: 19699854 Clinical Trial.
Antithrombotics in acute coronary syndromes.
Bonaca MP, Steg PG, Feldman LJ, Canales JF, Ferguson JJ, Wallentin L, Califf RM, Harrington RA, Giugliano RP. Bonaca MP, et al. J Am Coll Cardiol. 2009 Sep 8;54(11):969-84. doi: 10.1016/j.jacc.2009.03.083. J Am Coll Cardiol. 2009. PMID: 19729112 Free article. Review.
292 results